SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 69 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $263,000 | -74.4% | 221,071 | -29.9% | 0.00% | – |
| Q4 2021 | $1,028,000 | +12.0% | 315,195 | +53.5% | 0.00% | – |
| Q3 2021 | $918,000 | -45.4% | 205,303 | -33.5% | 0.00% | -100.0% |
| Q2 2021 | $1,682,000 | -36.0% | 308,651 | -12.1% | 0.00% | 0.0% |
| Q1 2021 | $2,627,000 | -52.1% | 351,169 | -30.5% | 0.00% | -50.0% |
| Q4 2020 | $5,480,000 | +10.1% | 505,079 | -10.3% | 0.00% | 0.0% |
| Q3 2020 | $4,976,000 | -17.2% | 562,802 | -0.2% | 0.00% | -33.3% |
| Q2 2020 | $6,010,000 | +79.8% | 563,772 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $3,343,000 | -3.5% | 563,772 | +12.4% | 0.00% | +100.0% |
| Q4 2019 | $3,466,000 | -29.7% | 501,529 | +5.7% | 0.00% | -50.0% |
| Q3 2019 | $4,927,000 | +12.1% | 474,616 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $4,394,000 | +32.3% | 474,616 | +30.6% | 0.00% | +100.0% |
| Q1 2019 | $3,322,000 | +144.3% | 363,442 | +48.9% | 0.00% | 0.0% |
| Q4 2018 | $1,360,000 | -24.1% | 244,080 | +62.3% | 0.00% | 0.0% |
| Q3 2018 | $1,791,000 | – | 150,352 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 4,806,656 | $58,449,000 | 19.02% |
| Casdin Capital, LLC | 182,141 | $2,215,000 | 1.83% |
| Aisling Capital LLC | 508,565 | $6,184,000 | 1.44% |
| Redmile Group, LLC | 948,440 | $11,533,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,812,778 | $22,043,000 | 0.91% |
| EcoR1 Capital, LLC | 63,596 | $773,000 | 0.25% |
| Eventide Asset Management | 150,000 | $1,824,000 | 0.12% |
| AWM Investment Company, Inc. | 47,550 | $578,000 | 0.11% |
| Weiss Multi-Strategy Advisers LLC | 49,000 | $596,000 | 0.03% |
| Baker Brothers Advisors | 204,465 | $2,486,000 | 0.02% |